Bristol-Myers Reports Received Positive CHMP Opinion Recommending Approval Of Empliciti Plus Pomalidomide, Low-Dose Dexamethasone For Treatment Of Patients with Relapse, Refractory Multiple Myeloma
Benzinga Newsdesk